Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr tells Proative its Onapristone extended-release has shown significantly increased suppression of tumor cell proliferation in postmenopausal patients with progesterone receptor-positive (PR+) early breast cancer.
The positive data came from the window-of-opportunity clinical trial of ONA-XR and was presented during the 2021 San Antonio Breast Cancer Symposium (SABCS).